Biopioneer: Striving to be a Change-bringer Backed by a Passion for Innovation

  Dr. Bijayananda Panigrahi,    Founder & Managing Director

Dr. Bijayananda Panigrahi

Founder & Managing Director

The pursuit of excellence and consistent improvement is what separates industry leading pioneering business organization from the rest. While most want to generate revenue for them and their business, very few goes above and beyond to have an impact on peoples’ lives. Biopioneer is one such company and under the expert guidance of industry stalwart Dr. Bijayananda Panigrahi, Biopioneer has been able to develop into an innovation driven company which is focused on developing products to accelerate scientific R&D. The company strives to create products that target the very basic existing gaps in the market in a more cost-effective manner. As of now, Biopioneer is working on developing innovative protease inhibitors that have several unique qualities which make them stand out from all the popular protease inhibitors on the market. This BIRAC-BIG and StartUP Odisha funded company was also featured in Industrial Outlook as one of the top 10 Biotech startups in Odisha which acts as a testament that further showcases their quality.

Biopioneer offers novel protease inhibitors that have several key unique points that make it stand out from the crowd. Adding more about their uniqueness, Dr. Bijayananda says “Our protease inhibitors cover several gaps that prevail in the current protease inhibitor market. Protease inhibitors that are currently available in the market are made up of a variety of organic and inorganic compounds that work against various enzymes. Furthermore, their toxicity, as well as their high cost, limit their employment in a variety of applications. Our newly developed substance, on the other hand, is a single component that is stable at room temperature, non-toxic, water soluble, and effective”.

Studies revealed that the new material could inhibit serine protease significantly (around 97 percent). It also exhibits inhibitory action against strong proteases such as proteinase K, trypsin, chymotrypsin, pepsin, cathepsin B, papain, bromelain, lysozyme, kallikrein-3, subtilisin, elastase, and thrombin. Especially, proteinase K inhibition is rarely seen in the case of traditional protease inhibitors. This supports the unique nature of the newly
developed material. Apart from the above-mentioned features, the NexGen HM protease inhibitor is less expensive than traditional protease inhibitors.

It has shown its stability at very high temperatures up to 100°C and is stable at room temperatures for almost two years which is a major reason for its cost-effectiveness.Considering all the facts, it can be predicted that the new NexGen HM Protease inhibitor could be a promising protease inhibitor. There are also multiple other facets that makes this product unique in the market. These USPs include: It is a single material having multiple protease inhibition abilities, It is compatible with different buffer conditions, It is water soluble, and It has zero interference in fluorescence-based protein quantification to mention a few.

Our protease inhibitors cover several gaps that prevail in the current protease inhibitor market

An Emerging Industry Leader
With this, Biopioneer has been able to make a name for themselves in the industry and break new business frontiers. Apart from this, Biopioneer has other products as well in their portfolio and these include different protein-specific inhibitors such as Proteinase K Inhibitor, Cathepsin B Inhibitor, Kallikrein-3 Inhibitor, and some more like them. There have been many success stories for the company over the years including in 2022 January when they started giving out free trial samples to some of the institutions across Bhubaneswar and some outside Odisha as well and asked for feedback testimonials from them. To the company’s surprise, they received excellent responses from their customers from institutions like AIIMS, ICGEB New Delhi, Imgenex, Utkal University, ILS, and KIIT, Bhubaneswar. And as of now, all of them are ready to purchase from Biopioneer as well.

Biopioneer is a frontrunner when it comes to technology adoption and to synthesize and validate the NexGen HM protease inhibitor, the company uses different high through put techniques such as SDS-PAGE, fluorescence spectroscopy, ELISA reader, Western blot, and ultra sonication unit to name a few. Evolving with the changing market conditions, Biopioneer aspires to continue being at the front of bleeding-edge technologies in the coming years as well.

Even with the success they had in the industry, Biopioneeris not ready to rest on their laurels and talking about their future plans, Dr. Bijayananda adds, “NexGen HM protease inhibitor is the first product which we are introducing in the market. Further, we plan to come up with a more efficient NexGen Proteinase K Inhibitor, and NexGen Pronase E inhibitor. In the next couple of years, This startup will be focusing on the optimization of production from a lab-scale to an industrial scale. Meanwhile, building strong marketing strategies and partnerships with industries will be their top priority. Further, the company aims to launch the product globally by 2025”.